U.S. markets close in 57 minutes
  • S&P 500

    4,070.72
    -5.85 (-0.14%)
     
  • Dow 30

    34,422.47
    +27.46 (+0.08%)
     
  • Nasdaq

    11,444.53
    -37.92 (-0.33%)
     
  • Russell 2000

    1,887.36
    +5.68 (+0.30%)
     
  • Crude Oil

    80.08
    -1.14 (-1.40%)
     
  • Gold

    1,811.10
    -4.10 (-0.23%)
     
  • Silver

    23.13
    +0.49 (+2.18%)
     
  • EUR/USD

    1.0536
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    3.5150
    -0.0140 (-0.40%)
     
  • GBP/USD

    1.2292
    +0.0036 (+0.29%)
     
  • USD/JPY

    134.4530
    -0.8530 (-0.63%)
     
  • BTC-USD

    16,990.69
    +40.16 (+0.24%)
     
  • CMC Crypto 200

    403.60
    +2.18 (+0.54%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England, October 05, 2022--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 18,000 shares of KalVista common stock on October 3, 2022 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $14.24 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve treatment for people living with HAE. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information, please visit www.kalvista.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005298/en/

Contacts

KalVista Pharmaceuticals, Inc.
Jarrod Aldom
Vice President, Corporate Communications
(201) 705-0254
jarrod.aldom@kalvista.com